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Abstract
Background: Renal failure is a frequent complication of multiple myeloma and when severe is
associated with a greatly increased morbidity and mortality. The principal cause of severe renal
failure is cast nephropathy, a direct consequence of high concentrations of monoclonal free light
chains (FLCs) in patients' sera. FLC removal by extended haemodialysis, using a high cut-off dialyser,
has recently been described as a novel therapeutic option.
Methods: The EUropean trial of free LIght chain removal by exTEnded haemodialysis in cast
nephropathy (EuLITE) trial is a prospective, randomised, multicentre, open label clinical trial to
investigate the clinical benefits of FLC removal haemodialysis in patients with cast nephropathy,
dialysis dependent acute renal failure and de novo multiple myeloma. Recruitment commenced in
May 2008. In total, 90 patients will be recruited. Participants will be randomised, centrally, upon
enrolment, to either trial chemotherapy and FLC removal haemodialysis or trial chemotherapy and
standard high flux haemodialysis. Trial chemotherapy consists of bortezomib, doxorubicin and
dexamethasone. FLC removal haemodialysis is undertaken with two Gambro HCO 1100 dialysers
in series using an intensive treatment schedule. The primary outcome for the study is independence
of dialysis at 3 months. Secondary outcomes are: duration of dialysis, reduction in serum FLC
concentrations; myeloma response and survival.
Hypothesis: FLC removal haemodialysis will increase the rate of renal recovery in patients with
severe renal failure secondary to cast nephropathy in de novo multiple myeloma.
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Background
Renal impairment is a frequent complication of multiple
myeloma affecting between 18 and 56% of patients at
presentation [1-4]. When severe it is associated with a
greatly increased morbidity and mortality. However,
improvement of renal function also improves the
patients' survival [2,5,6]. Previous studies have demon-
strated that the principal cause of severe renal failure in
patients with multiple myeloma is cast nephropathy, a
direct consequence of the high concentrations of mono-
clonal free light chains (FLCs) in the patients' sera.
Treatment strategies for patients with severe renal failure
and multiple myeloma should first focus on correcting
reversible factors such as dehydration and hypercalcaemia
[7]. Second, disease specific treatments should be initiated
rapidly and there is growing evidence for the role of new
chemotherapeutic agents [8-10]. The third treatment
option for these patients is direct removal of monoclonal
FLCs from the serum. Historically, this has been under-
taken using plasma exchange, however the efficacy of this
treatment has never been established [11-13].
Recently we described the removal of FLCs by extended
haemodialysis, using the Gambro HCO 1100, as an alter-
native strategy [14]. Results of early pilot studies suggest
that the procedure is not only effective at removing FLCs,
but it is also associated with improved clinical outcome
[6,15]. In 17 patients with cast nephropathy treated, 12
recovered sufficient renal function to become independ-
ent of dialysis. This rate was a significantly higher than
that of a case matched control population from the same
institution, P < 0.01 [6].
The purpose of the EuLITE trial is to evaluate, in a control-
led setting, FLC removal haemodialysis in patients with




The EuLITE trial examines the hypothesis that FLC
removal haemodialysis will increase the rate of renal
recovery in patients with cast nephropathy, severe renal
failure and de novo multiple myeloma.
Design
The EuLITE trial is a prospective, randomised, multicen-
tre, open label clinical trial to investigate the clinical ben-
efit of FLC removal haemodialysis in patients with cast
nephropathy, dialysis dependent renal failure and de novo
multiple myeloma [16]. Inclusion and exclusion criteria
are detailed in Table 1. At enrolment patients are ran-
domised into one of two treatment groups (Figure 1):
Group A (intervention): This group will receive extended
haemodialysis using Gambro HCO 1100 dialysers and
standard trial chemotherapy of: bortezomib, doxorubicin
and dexamethasone.
Group B (control): This group will receive standard high
flux haemodialysis (using a Gambro Polyflux-S dialyser)
at intervals determined on clinical grounds by the neph-
rologist supervising care (minimum 4 hours 3 times per
week) and standard trial chemotherapy of: bortezomib,
doxorubicin and dexamethasone.
Randomisation is undertaken using random number gen-
eration by the programme Datinf RandGen (Datinf, Tub-
ingen, Germany). The minimization algorithm described
by Pockock and Simon [17] was employed to ensure bal-
ance between the intervention age groups (18–55, 56–65,
66–75 and 75+) and study centre. The allocation is made
at random with a weighting in favour of the intervention
that would minimize imbalance with a probability of 0.8.
The seed for random number generation is stored securely
to allow reproduction of the random numbers if required.
Study chemotherapy (both groups)
The first six patients entered into the study will comprise
a cohort assessed for the safety of a reduced dose PAD reg-
imen [18]. The modified regimen will consist of: borte-
zomib (1 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle);
doxorubicin (9 mg/m2 on days 1 and 4 of the 21 day
cycle) and dexamethasone (40 mg daily days 1–4, 8–11
and 15–18 for the first 21 day cycle and days 1–4 only on
subsequent cycles). This safety assessment will be inde-
pendent of the renal therapy to which they have been
assigned.
Supportive therapy:
 Co-trimoxazole 480 mg three times per week or alterna-
tive Pneumocystic carinii prophylaxis as per local institu-
tional practice.
 Ranitidine 150 mg twice daily whilst on dexamethasone
 Metoclopramide 10–20 mg three times per day as
required (20 mg to be given pre-chemo on day 1)
 Allopurinol 100 mg orally daily
 Aciclovir 200 mg twice per day, orally
Chemotherapy may have to be stopped or withheld for
medical reasons. Such patients will be withdrawn from
the treatment group and revert to standard care for their
dialysis unit. Patients who withdraw for any reason willTrials 2008, 9:55 http://www.trialsjournal.com/content/9/1/55
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still be followed-up for all outcome measures, in order to
enable an 'intention to treat analysis'.
FLC removal haemodialysis (group A only)
Participants will receive haemodialysis on non-borte-
zomib days: 6 hours on day 0, then 8 hours on days 2, 3,
5–7, 9+10. After day 12, participants will receive 8 hours
of haemodialysis on alternate days. Dialysis will be under-
taken using two Gambro HCO 1100 dialysers in series at
a blood flow of 250 ml/min, dialysate flow of 500 ml/
min, with adequate heparin (activated clotting time of
180–200 seconds). The supervising clinician will deter-
mine the fluid removal, with the aim to not dehydrate the
patient.
Extended FLC removal haemodialysis will be supported
by replacement of human albumin solution, in the last
hour of each dialysis session (60 g). Magnesium, calcium
and potassium will be replaced as required. After day 21,
if patients still requires renal support the dialysis schedule
will be reduced to 6 hours three times per week.
Primary endpoint
The primary endpoint of the study is independence of
dialysis at three months from enrolment. Independence
of dialysis will be defined as an estimated GFR of > 15
mls/min/1.73 m2, 2 weeks after the last dialysis session.
Patients' renal function will be assessed by biochemical
markers (urea, creatinine and an estimated GFR) with
monitoring of urine output. Patients who have a pre-dial-
ysis eGFR of > 20 ml/min and a good urine out-put should
receive a trial with out dialysis. The nephrologist respon-
sible for the patients' care will decide when this is suitable.
Patients who become independent of dialysis during the
first 90 days, but subsequently require further dialysis
support, so that they are dialysis dependent at the 3
month point will be classified as treatment failures.
Secondary endpoints
The first secondary endpoint is to determine the efficiency
of FLC removal HD that results in sustained reductions in
serum FLC concentrations versus a standard dialysis.
Serum FLC concentrations will be measured pre- and
post-dialysis, daily for the first 21 days on dialysis days.
It is proposed that patients with a cast nephropathy will
recover their renal function more rapidly if their serum
FLC concentrations are reduced quickly. We will, there-
fore, observe the duration of requirement for HD.
The management of patients with multiple myeloma is
limited by renal impairment. It is conceivable that
patients who recover renal function will have an increased
chance of being suitable for high dose melphalan and
stem cell transplantation, which is the current standard of
care after primary chemotherapy. Response to treatment
Table 1: Inclusion and exclusion criteria
Inclusion criteria
 Age greater than 18 years
 Dialysis dependent acute renal failure (defined by: an estimated GFR of < 15 ml/min/1.73 m2)
 Fulfils criteria for the diagnosis of symptomatic de novo multiple myeloma
 Abnormal serum FLC ratio and a serum FLC concentration > 500 mg/L
 Myeloma kidney demonstrated on a renal biopsy (cast nephropathy)
 Commencement of study within 10 days of presenting to enrolling unit
Exclusion criteria
 Known advanced chronic renal failure (eGFR < 30 mls/min/1.73 m2) or evidence of significant chronic damage on renal biopsy
 Amyloidosis or light chain deposition disease on renal biopsy
 Previous treatment of multiple myeloma with chemotherapy
 Haemodynamic instability that precludes unsupported renal replacement therapy
 Significant cardiac disease
 Advanced disease or significant co-morbidity: with poor short term prognosis, necessitating palliation and no active or disease specific 
treatment.
 History of allergic reaction attributable to compounds containing boron or mannitol
 Peripheral neuropathy or neuropathic pain Grade 2 or higher
 Clinically significant liver dysfunction (bilirubin > 1.8 mg/dl (30 umol/L))
 Active uncontrolled infection or known HIV infection
 Inability to give informed consent
 Pregnant and lactating womenTrials 2008, 9:55 http://www.trialsjournal.com/content/9/1/55
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of multiple myeloma will be documented at the end of
each chemotherapy cycle, then 6 and 12 months. Whether
patients under 70 years of age have received a stem cell
transplant will be recorded at 12 months.
Renal failure is the second commonest cause of death in
patients with multiple myeloma. Therefore, patients who
recover renal function should have a lower mortality rate.
Overall survival will be recorded in both arms of the
study.
Case report forms and data collection
All study data will be recorded on electronic Case Report
Forms (eCRF) which are generated on a dedicated ran-
domisation and remote data entry web server (Datinf,
Tubingen, GmbH). The CRFs will be completed and
signed by the local investigator or his/her designee as
soon as the requested information is available. During the
first 21 days, eCRFs will be completed for each dialysis
day. These document the details of dialysis (including any
breaches in protocol), biochemistry and haematological
data. A specific eCRF is completed at the end of each
chemotherapy cycle to document compliance with chem-
otherapy protocol. Time points for clinical and laboratory
data are at the end of each cycle of chemotherapy and 3,
6, and 12 months.
Chemotherapy response
After a maximum of 4 cycles of treatment, patients will be
assessed for response to PAD chemotherapy according to
the International uniform response criteria for multiple
myeloma [19]. If there is no evidence of response i.e. sta-
ble disease or progressive disease, then the patient will
have been deemed to have failed PAD chemotherapy, and
treatment will be switched to a regimen compatible with
local institutional practice. Patients with a partial
response or very good partial response will be eligible to
continue for a maximum of 8 cycles. Patients who have
achieved a stringent complete response or complete
response will be eligible to stop chemotherapy and pro-
ceed to autologous peripheral blood stem cell collection if
considered suitable for high dose therapy and stem cell
rescue.
Statistical analysis plan
The primary analysis for the trial is to compare the exper-
imental treatment with the control treatment in terms of
independence of dialysis at three months. The proportion
of patients independent of dialysis will be compared
using point and interval estimates of relative risks and
continuity-adjusted chi-square tests. The analysis will be
carried out on an intention-to-treat basis. Due to the short
follow-up required for the primary endpoint, missing data
are not expected but the analysis will include these as fail-
ures and sensitivity analysis will assess the robustness of
the conclusions to this assumption. As an additional anal-
ysis, time taken for independence of dialysis to occur will
be compared between the two groups. Times will be cen-
sored for those patients who are not independent of dial-
ysis at the time of analysis or lost to follow-up. Kaplan-
Meier estimation and log-rank tests will be used to com-
pare the groups.
The change in serum FLC concentrations over time will be
compared across the two groups using longitudinal anal-
ysis with imputation used for any missing data. In partic-
ular, the treatment groups will be compared in terms of
changes in mean pre-dialysis serum FLC concentrations
for days 4–6, 8–10 and 20–22 relative to the pre-randomi-
zation level using analysis of variance. The appropriate
parametric or non-parametric version of this analysis will
be determined by graphical assessment of the normality
of the data. Myeloma response at 6 and 12 months, and
the proportion to have undergone a peripheral blood
stem cell transplant at 12 months, will be compared
across treatment groups using estimates of relative risks
and continuity-adjusted chi-square tests. Mortality will be
documented for a follow-up period of 24 months. Sur-
vival time will be censored for those patients still alive at
the time of analysis or lost to follow-up and Kaplan-Meier
estimation and log-rank tests will be used to compare
treatment groups.
The balance of baseline factors across the two treatment
groups will be assessed descriptively as hypothesis testing
is not appropriate in this randomised setting. The key
baseline factor in this setting is age which will be stratified
for in the randomisation procedure. Analysis of the pri-
mary outcome measure will adjust for age using logistic
regression modeling to ensure that the validity of the con-
clusions. Appropriate modeling will also be used to adjust
for baseline factors in the analysis of any secondary out-
comes.
Timing of analysis
Interim analysis will be carried out 3 months after the first
25 patients have been recruited and then when recruit-
ment of 50% of target has been achieved. Data will be pre-
sented to an independent Data Monitoring Committee.
The interim analysis will present recruitment data and
data on outcomes and adverse events. Given the small size
of the study, the interim analysis will be purely descriptive
with the primary aim to assess patient safety and that it is
ethical to continue. The study is expected to complete
recruitment within 1 year. Final analysis will be carried
out after all patients have been followed up for a mini-
mum of 3 months and a further analysis of the survival
outcome will be carried out after all patients have been
followed-up for a minimum of 24 months.Trials 2008, 9:55 http://www.trialsjournal.com/content/9/1/55
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Calculation of sample size
Sample size calculations are based on the primary out-
come of independence of dialysis after 3 months from
enrolment. Data from previous studies suggest a recovery
rate of 25% in the control group and suggest that an
improvement to 55% in the treatment group is a realistic
expectation. Assuming an alpha error level of 5%, 41
patients are required in each treatment arm to detect this
size of difference with 80% power. The primary analysis
will be on an intention-to-treat basis but to enable suffi-
cient power for any per-protocol analysis the final target is
increased by 10% to allow for patients who withdraw
from protocol treatment at the discretion of the treating
physician. These patients will be followed-up for all out-
come measures unless consent is withdrawn. The target
recruitment is therefore 45 patients per arm, 90 patients in
total.
Safety assessments
Safety assessments will include the monitoring and
recording of all adverse events, including serious adverse
events. Serious adverse events that are unexpected and
considered by the investigator to be related to bortezomib
will be reported to the ethics committee and the Medi-
cines and Healthcare Products Regulatory Agency.
Expected adverse events are presented in Table 2, unex-
pected are those not given. Grading and causality of the
events will be undertaken by the site investigator and
reviewed by the principal investigator.
Summary
This trial will investigate the potential role of FLC removal
haemodialysis in the management of patients with new
multiple myeloma, cast nephropathy and dialysis
dependent renal failure. If efficacious this therapy will
offer clinicians new options in the management of these
patients with historically very poor outcome.
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Table 2: Expected adverse events
Dialysis related Chemotherapy related
 Hypotension during dialysis  Infections and infestations
 Dialysis line exit site infection  Neoplasms benign, malignant and unspecified
 Cardiac arrhythmia  Blood and lymphatic system disorders
 Septicaemia  Immune system disorders
 Endocarditis  Endocrine disorders
 Fluid overload  Metabolism and nutrition disorders
 Peripheral oedema  Psychiatric disorders
 Hypoalbuminemia  Nervous system disorders
 Hypophosphatemia, hypomagnesemia, hypokalaemia, hypocalcaemia  Eye disorders
 Hypersensitivity reactions  Ear and labyrinth disorders
 Cardiac disorders (including cardiac tamponade)
 Vascular disorders
 Respiratory, thoracic and mediastinal disorders (including 
Pneumonitis, interstitial pneumonia, Acute Respiratory Distress 
Syndrome)
 Gastrointestinal disorders 
(including ischemic colitis and liver failure, hepatobiliary disorders)
 Skin and subcutaneous tissue disorders
 Musculoskeletal and connective tissue disorders
 Renal and urinary disorders
 Reproductive system and breast disorders
 Herpes meningoencephalitis
 Angioedema
 Encephalopathy, autonomic neuropathy
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